Cargando…

Hydroxychloroquine/immunosuppressants: Nosocomial coronavirus disease 2019 (COVID-19), leucopenia and prolonged persistence of COVID-19 following off-label use: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378984/ http://dx.doi.org/10.1007/s40278-020-81159-y

Ejemplares similares

Etoposide: Leucopenia and enterococcal infection following off-label use: case report
Publicado: (2020)

Chloroquine/tocilizumab: Leucopenia and liver injury following off-label use: case report
Publicado: (2020)

Hydroxychloroquine: QTc prolongation following off-label-use: case report
Publicado: (2020)

Hydroxychloroquine: QTc-prolongation following an off-label use: case report
Publicado: (2020)

Hydroxychloroquine: QTc prolongation following off-label use: case report
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Immunosuppressants/azithromycin: Prolonged COVID-19 infection, off label use and lack of efficacy: case report
Publicado: (2021)

Hydroxychloroquine: Prolonged QT interval following off label use: case report
Publicado: (2020)

Hydroxychloroquine: Prolonged QTc interval following off-label use: case report
Publicado: (2020)

Hydroxychloroquine: QTc interval prolonged following off label use: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: QT prolongation following off label use: case report
Publicado: (2022)

Hydroxychloroquine: QT interval prolongation following off-label use: case report
Publicado: (2022)

Multiple drugs: COVID-2019-infection, myasthenic crisis and off-label treatment with hydroxychloroquine and azithromycin for COVID-19 : case report
Publicado: (2020)

Hydroxychloroquine: QT prolongation due to off-label use: case report
Publicado: (2022)

Deferasirox/hydroxychloroquine: Various toxicities and off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Hydroxychloroquine: Sinus bradycardia and QTc prolongation following off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolonged corrected QT following off label use: case report.
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc prolongation following off-label use: 2 case reports
Publicado: (2021)

Immunosuppressants: Lymphopenia, neutropenia and prolongation of the coronavirus disease 2019 (COVID-19) viral clearance: case report
Publicado: (2021)

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
por: Sahraei, Zahra, et al.
Publicado: (2020)

Vancomycin: Myeloid maturation arrest in the form of leucopenia and promyelocyte proliferation following off label use: case report
Publicado: (2022)

Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2022)

Cladribine/hydroxychloroquine: COVID-19-pneumonia, lymphopenia and off label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine/tocilizumab: QTc prolongation and off label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc prolongation and off label use: 3 case reports.
Publicado: (2021)

Azithromycin/hydroxychloroquine: QTc prolongation during off-label treatment: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: Prolonged QTc during off label use: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: Ventricular arrhythmias following off-label use in COVID-19: 2 case reports
Publicado: (2020)

Azithromycin/hydroxychloroquine interaction: QT interval prolongation following off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: Corrected QT-interval prolongation following off label use: case report
Publicado: (2020)

Hydroxychloroquine: Electrical storm and QT interval prolongation following off-label use: case report
Publicado: (2020)

Hydroxychloroquine: Persistent increase in QTc interval following off-label use: case report
Publicado: (2022)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID-19) and QTc prolongation
por: Changal, Khalid, et al.
Publicado: (2021)

Editorial: Impact of coronavirus disease 2019 (COVID-19) pandemic on nosocomial infection
por: Wang, Mingke, et al.
Publicado: (2023)

Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation
por: Belayneh, Anteneh
Publicado: (2020)

Dexamethasone/hydroxychloroquine: Reactivation of COVID-19 infection and off label use: 4 case reports
Publicado: (2021)

Hydroxychloroquine: Borderline prolongation of QTc interval during off-label treatment: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolonged QT interval during off label use: case report
Publicado: (2021)

Antivirals/immunosuppressants: COVID-19 infection and off label use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1adnk85g2udmqvrl7q76k89asv